FDCP
TXG icon

Foster Dykema Cabot & Partners’s 10x Genomics TXG Stock Holding History

Foster Dykema Cabot & Partners’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12
Closed -$271 – 488
2024
Q3 		$271 Buy
+12
New +$248 ﹤0.01% 501

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Foster Dykema Cabot & Partners's TXG Position: Q4 2024 in Review

Foster Dykema Cabot & Partners sold out of 10x Genomics (TXG) in Q4 2024, closing a stake of 12 shares — an estimated $271 sold.

Foster Dykema Cabot & Partners first reported a position in TXG in Q3 2024 and held it in 1 quarter. The position peaked at $271 in Q3 2024. 273 funds tracked by Wall St. Rank hold TXG as of Q4 2024.

  • Foster Dykema Cabot & Partners reported no remaining 10x Genomics position as of Q4 2024 after selling out during the quarter.
  • Foster Dykema Cabot & Partners sold 12 10x Genomics shares in Q4 2024, an estimated $271.
  • Foster Dykema Cabot & Partners first reported a position in 10x Genomics in Q3 2024 and held it in 1 quarter.
  • Foster Dykema Cabot & Partners's 10x Genomics position peaked at $271 in Q3 2024.
  • 273 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2024.

Based on Foster Dykema Cabot & Partners's 13F filing for Q4 2024, filed 13 Feb 2025.